Skip to main content
. Author manuscript; available in PMC: 2024 Apr 10.
Published in final edited form as: Ann Rheum Dis. 2022 Sep 15;82(2):262–271. doi: 10.1136/ard-2021-221269

Table 1.

HDAC inhibitors with significant activity in the FoxO1 drug screen.

Drug EC50
Panobinostat (LBH589) 4.15329E-08
Vorinostat (SAHA) 8.62446E-08
Dacinostat (LAQ824) 1.43602E-07
Givinostat 1.52729E-07
QUISINOSTAT 1.55606E-07
AR-42 2.78339E-07
Pracinostat (SB939) 3.15689E-07
Abexinostat (PCI-24781) 3.67361E-07
Ivaltiniostat (CG-200745) 4.13034E-07
JNJ-16241199 4.30184E-07
EVP-0334 4.8753E-07
CUDC-101 5.14518E-07
M344 9.07171E-07
Belinostat (PXD101) 1.41954E-06
CAY10603 1.67958E-06
CHR-3996 1.79217E-06
Resminostat (RAS2410) 2.20604E-06
Scriptaid 2.29618E-06
Rocilinostat (ACY-1215) 2.51576E-06
Pyroxamide 3.47248E-06
CY-190602 5.18846E-06
Oxamflatin 6.39766E-06
CXD101 6.60552E-06
Tacedinaline 5.14518E-07